Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Epidemiol Infect ; 144(14): 3017-3024, 2016 10.
Article in English | MEDLINE | ID: mdl-27373141

ABSTRACT

This study describes epidemiological trends for acute rotavirus gastroenteritis (RVGE) in Belgium in children aged ⩽5 years during the period June 2007 to May 2014 after the introduction of routine rotavirus (RV) vaccination. This period encompassed the switch from lyophilized to the liquid formulation of Rotarix™ (GlaxoSmithKline, Belgium) in August 2011. Uptake of RV vaccine remained consistently high throughout the study period with Rotarix the brand most often used. RV was present in 9% (1139/12 511) of hospitalized cases with acute gastroenteritis included in the study. Epidemiological trends for hospital admissions for RVGE remained consistent throughout the study period, with no evidence of any change associated with the switch from lyophilized to liquid formulation of Rotarix. This suggests both formulations perform similarly, with the liquid formulation not inferior regarding ability to reduce hospital admissions for acute RVGE in children aged ⩽5 years. A strong seasonal effect was observed with most RVGE occurring in the winter months but with some variability in intensity, with highest incidence found in those aged 6-24 months. The main observation was the decreased number of hospital admissions for RVGE in Belgium that occurred during winter 2013/2014.


Subject(s)
Hospitalization , Rotavirus Infections/epidemiology , Rotavirus Vaccines/therapeutic use , Rotavirus/immunology , Vaccination , Acute Disease , Belgium/epidemiology , Child, Preschool , Female , Hospitalization/statistics & numerical data , Hospitalization/trends , Humans , Infant , Infant, Newborn , Male , Rotavirus Infections/prevention & control , Rotavirus Infections/virology , Vaccination/statistics & numerical data , Vaccines, Attenuated/therapeutic use
5.
Horm Res Paediatr ; 79(5): 257-70, 2013.
Article in English | MEDLINE | ID: mdl-23735882

ABSTRACT

The goal of growth hormone (GH) treatment in a short child is to attain a fast catch-up growth toward the target height (TH) standard deviation score (SDS), followed by a maintenance phase, a proper pubertal height gain, and an adult height close to TH. The short-term response variable of GH treatment, first-year height velocity (HV) (cm/year or change in height SDS), can either be compared with GH response charts for diagnosis, age and gender, or with predicted HV based on prediction models. Three types of prediction models have been described: the Kabi International Growth Hormone Study models, the Gothenburg models and the Cologne model. With these models, 50-80% of the variance could be explained. When used prospectively, individualized dosing reduces the variation in growth response in comparison with a fixed dose per body weight. Insulin-like growth factor-I-based dose titration also led to a decrease in the variation. It is uncertain whether adding biochemical, genetic or proteomic markers may improve the accuracy of the prediction. Prediction models may lead to a more evidence-based approach to determine the GH dose regimen and may reduce the drug costs for GH treatment. There is a need for user-friendly software programs to make prediction models easily available in the clinic.


Subject(s)
Growth Disorders/drug therapy , Human Growth Hormone/therapeutic use , Models, Biological , Adolescent , Adult , Age Factors , Biomarkers/metabolism , Child , Child, Preschool , Female , Growth Disorders/physiopathology , Humans , Insulin-Like Growth Factor I/metabolism , Male , Sex Factors
6.
Curr Med Res Opin ; 25(8): 2049-59, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19575628

ABSTRACT

OBJECTIVE: To evaluate the cost-effectiveness of micafungin compared to caspofungin in the treatment of systemic Candida infections (SCIs) in the UK, including invasive candidiasis and candidaemia. RESEARCH DESIGN AND METHODS: Cost-effectiveness of both echinocandin antifungal drugs was estimated using decision analysis. Response to treatment, resource utilisation, and costs in the model were derived from a phase 3, head-to-head comparative trial. The model includes only data directly related to the treatment of the systemic Candida infection over the study duration (a maximum period of 14 weeks). Transition probabilities were calculated based on the efficacy results from the clinical trial. MAIN OUTCOME MEASURES: The model's effectiveness outcome is surviving patients who are successfully treated, based on the absence of signs and symptoms, radiographic abnormalities, and culture/histologic evidence associated with the fungal infection. In addition, subgroup analyses were performed to identify cost-effectiveness in several specific patient groups. RESULTS: The total medical treatment costs for the micafungin group were pound 29,095, which is similar to the total costs for the caspofungin group (pound 29,953). In the micafungin arm 60% of the patients and in the caspofungin arm 58% of the patients were successfully treated and alive. Cost-effectiveness ratio of micafungin was pound 48,771, and of caspofungin pound 52,066 per successfully treated patient. Because the costs are lower and the effectiveness is higher for micafungin in comparison with caspofungin, micafungin is more cost-effective than caspofungin. However, probabilistic sensitivity and subgroup analysis show that the differences cannot be considered significant due to a large variance although micafungin remained the most cost-effective option throughout all but one of the sensitivity analyses. CONCLUSIONS: Costs and effects of micafungin compare to those of caspofungin in the treatment of systemic Candida infections in the UK. The results indicate that micafungin is cost-effective compared to caspofungin, although the difference was not found to be significant.


Subject(s)
Antifungal Agents/economics , Candidiasis/drug therapy , Echinocandins/economics , Lipopeptides/economics , Adolescent , Adult , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Candidiasis/physiopathology , Caspofungin , Clinical Trials, Phase III as Topic , Cost-Benefit Analysis , Echinocandins/administration & dosage , Echinocandins/therapeutic use , Economics, Pharmaceutical , Health Care Costs , Humans , Lipopeptides/administration & dosage , Lipopeptides/therapeutic use , Micafungin , Middle Aged , Models, Economic , United Kingdom , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...